MONROL
28.9.2022 15:28:36 CEST | Business Wire | Press release
Following an ongoing assessment of its entire operation, Eczacıbaşı-Monrol Nuclear Products Co. (Monrol) has decided to establish a legal entity and manufacturing facility in Germany.
The new facility will focus on the manufacture of SPECT products and radiopharmaceutical products for radioligand therapy(*) such as Gallium-68 generator and n.c.a Lutetium-177. Developed by Monrol R&D teams, these products are widely used in the production of radiopharmaceuticals for cancer patients. The facility will also have a dedicated division for state-of-the art cGMP Contract Development and Manufacturing Organization (CDMO) services.
Monrol plans to make the site a center of excellence for both radiopharmaceutical production and scientific and industry collaborative efforts to create innovations. The facility is expected to be up and running by 2026 at an estimated cost of around 30 million euros.
(*) Targeted radioligand therapy is an innovative approach to cancer treatment that is considered to be one of the most remarkable and advanced therapies currently under study. Multiple clinical development programs and clinical trials around the world are testing this approach for various cancer types.
About Lutetium-177 n.c.a
Lutetium-177 n.c.a is a radioisotope of choice for targeted radionuclide therapy. Lu-177 n.c.a production process enables treatment options that have the potential to improve treatment outcomes for certain cancer patients. Unique properties of Lutetium-177 n.c.a make it a theranostically desirable radioisotope for peptide receptor radionuclide therapy (PRRT) to treat certain cancers like neuro endocrine tumors (NET) and prostate cancer; many clinical development programs are also testing the therapy for other cancers like ccRCC.
About Gallium-68
A gallium-68 generator is a device used to extract the positron-emitting isotope 68Ga of gallium from decaying germanium-68. The parent isotope 68Ge is easily utilized for in-hospital production of generator-produced 68Ga. Its decay product gallium-68 is extracted and employed in certain positron emission tomography nuclear medicine diagnostic procedures used for the diagnosis of cancer patients and direct tumor imaging.
About Monrol
Monrol is one of the world’s largest nuclear medicine companies and a leader in the development and manufacturing of GMP grade radioisotopes and radiopharmaceuticals. The company distributes its own portfolio of world-class radiopharmaceutical products to more than 50 countries around the globe from its headquarters in Istanbul. Committed to transforming and improving patient journeys in cancer treatment, Monrol also provides early development support to CDMO customers as well as fully integrated services for taking new product concepts into clinical trials, demonstrating proof of concept, and moving into first-in-human studies. Located near a major international airport and transportation hub, Monrol benefits from a worldwide logistics network and agreements with cargo services to 320 destinations worldwide. To learn more, visit www.monrol.com and LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220928005666/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Humanoids Dominate the Headlines, but Specialized Physical AI Captures Value in $18 Billion Market, Arthur D. Little’s Blue Shift Finds3.9.2026 12:07:00 CEST | Press release
Arthur D. Little’s (ADL) Blue Shift, its forward-looking institute exploring the impact of emerging technologies on business and society, today published I, Robot. Despite the hype around humanoid robots, this report finds they are still immature, compared to other areas of physical AI (autonomous and versatile robots that can perceive, decide, and act in the physical world). ADL analysis shows that humanoid robots only account for $2-3 billion of today’s overall $18 billion physical AI market. Many demonstrations are pre-programmed, remotely operated or even totally AI-generated. The study highlights that specialized physical AI offers the real opportunity for innovation and value in the short-to-medium term, and that businesses should take action now. The overall market could reach $60-$100 billion by 2030, thanks to drivers including labor shortages, shifting work preferences, increasing needs for operational resilience and productivity pressures. Countries and regions are competing
LITEON Announces Strategic Investment in Liquid Cooling Technology Company DCX3.9.2026 12:05:00 CEST | Press release
Advancing AI Infrastructure Value Chain Through Integrated Power Management and Cooling Technologies LITEON Technology (2301.TW) today announced a strategic investment in DCX POLSKA Sp. z o.o. (“DCX Liquid Cooling Systems”), a Warsaw, Poland-based provider of advanced liquid cooling systems for AI and High-Performance Computing (HPC) data centers. Upon closing of the transaction, LITEON will hold approximately 25% equity ownership in DCX Liquid Cooling Systems with a total transaction value of approximately US$176 million. The investment brings together DCX's deep expertise in liquid cooling technologies, including coolant distribution units (CDUs), facility coolant distribution units (FDUs), cold plates and immersion cooling systems, with LITEON's strengths in AI server power management, rack-level power delivery and 800VDC power architectures. Together, the two companies are positioned to deliver highly integrated power and thermal management solutions for the rapidly evolving AI inf
The Untold Story ‘NEW YORK IN MONCLER’3.9.2026 12:00:00 CEST | Press release
A Retrospective of Pioneering New York Moments Some love stories take time. After decades of shared moments, Moncler reveals the story of its enduring relationship with New York through an expansive city-wide declaration of love. The untold story of New York in Moncler began when snow met concrete. What could have melted instead endured, forging a love built on pioneering moments and strengthened with every chapter. They found each other, again and again. Decades later, their story is finally ready to be shared. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260903671495/en/ NEW YORK IN MONCLER MIDTOWN MOUNTAINS Revealed through one of the largest open-air public exhibitions the city has ever seen, New York in Monclerunveils the peak moments that capture the bond between New York and Moncler, transforming communal spaces across the city into a powerful retrospective gallery from September 9-13. New York in Moncleris a very p
Chiesi Advances Its Carbon Minimal Inhaler Journey as European Submissions for Its Single Inhaler Triple Therapy (SITT) and ICS/LABA Combination Next-Generation Propellant pMDIs Are Validated3.9.2026 11:00:00 CEST | Press release
Key Highlights Regulatory submissions for next-generation propellant pMDIs (pressurized metered-dose inhalers) across Chiesi’s Single Inhaler Triple Therapy (SITT; or ICS/LABA/LAMA) and fixed double ICS/LABA combination (inhaled corticosteroid with a long-acting bronchodilator) range have been validated by Regulatory Agencies in Europe. Transition to HFA‑152a, a next‑generation propellant classified as non‑PFAS* and with low global warming potential (GWP),aimsto reduce the carbon footprint of Chiesi’s pMDIs by up to 90% compared to current ones.1-3 Designed for a seamless transition for patients and HCPs, maintaining established efficacy, safety and usability and supporting continuity of care.4-8 The validation supports Chiesi’s ambition to reach Net Zero† across its full value chain by 20359, following MHRA approval of Chiesi’s beclometasone pMDIs formulated with HFA-152a. Chiesi Group, an international research-focused biopharmaceutical company and certified B Corp, today announces a
Belkin præsenterer nye løsninger til at strømforsyne, lokalisere og personalisere hverdagens teknologi3.9.2026 10:00:00 CEST | Pressemeddelelse
Belkin International kan findes på IFA-messen i udstillingshal 3.2, stand nr. 117 Belkin, der i mere end 40 år har været globalt førende inden for forbrugerelektronik, annoncerede i dag en ny kollektion af tilsluttet tilbehør, enhedsbeskyttelse og livsstilsløsninger, der er designet til at hjælpe forbrugerne med at holde styr på og personalisere de enheder, de er afhængige af. Den nye portefølje omfatter SureFind-kollektionen, BoostCharge Slim Magnetic Ring Stand, UltraCharge Smart Display-powerbanks og nye farvevarianter af Belkins populære BoostCharge Compact USB-C-oplader 30 W. De nyligt annoncerede produkter bliver præsenteret på IFA 2026, hvor Belkin udstiller på IFA-messen i hal 3.2, stand nr. 117. Der er multimedier i denne pressemeddelelse. Se hele meddelelsen her: https://www.businesswire.com/news/home/20260903932800/da/ Product lineup showcasing Belkin's newest mobile power accessories De nye produkter bygger på idéen om, at teknologi skal passe problemfrit ind i en moderne l
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom